Terms: = Uterine cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Treatment
41 results:
1. Predicting Response to Immunotargeted Therapy in Endometrial cancer via Tumor Immune Microenvironment: A Multicenter, Observational Study.
Maltseva A; Kalinchuk A; Chernorubashkina N; Sisakyan V; Lots I; Gofman A; Anzhiganova Y; Martynova E; Zukov R; Aleksandrova E; Kolomiets L; Tashireva L
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612743
[TBL] [Abstract] [Full Text] [Related]
2. Brachytherapy for targeting the immune system in cervical cancer patients.
Linares I; Berenguer Frances MÁ; Cañas R; Najjari D; Gutiérrez C; Marín S; Comas S; Guedea F; Pujol M
BMC Immunol; 2023 Aug; 24(1):23. PubMed ID: 37559025
[TBL] [Abstract] [Full Text] [Related]
3. Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial.
Rodrigues M; Vanoni G; Loap P; Dubot C; Timperi E; Minsat M; Bazire L; Durdux C; Fourchotte V; Laas E; Pouget N; Castel-Ajgal Z; Marret G; Lesage L; Meseure D; Vincent-Salomon A; Lecompte L; Servant N; Vacher S; Bieche I; Malhaire C; Huchet V; Champion L; Kamal M; Amigorena S; Lantz O; Chevrier M; Romano E
Nat Commun; 2023 Jun; 14(1):3698. PubMed ID: 37349318
[TBL] [Abstract] [Full Text] [Related]
4. Increase of the T-reg-recruiting chemokine CCL22 expression in a progressive course of cervical dysplasia.
Vattai A; Kremer N; Meister S; Beyer S; Keilmann L; Buschmann C; Corradini S; Schmoeckel E; Kessler M; Mahner S; Jeschke U; Hertlein L; Kolben T
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6613-6623. PubMed ID: 36792811
[TBL] [Abstract] [Full Text] [Related]
5. Predictive value of an exosomal microRNA-based signature for tumor immunity in cervical cancer patients treated with chemoradiotherapy.
Someya M; Hasegawa T; Tsuchiya T; Kitagawa M; Fukushima Y; Gocho T; Mafune S; Ikeuchi Y; Kozuka Y; Idogawa M; Hirohashi Y; Torigoe T; Iwasaki M; Matsuura M; Saito T; Sakata KI
Med Mol Morphol; 2023 Mar; 56(1):38-45. PubMed ID: 36367588
[TBL] [Abstract] [Full Text] [Related]
6. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
López-Janeiro Á; Villalba-Esparza M; Brizzi ME; Jiménez-Sánchez D; Ruz-Caracuel I; Kadioglu E; Masetto I; Goubert V; Garcia-Ros D; Melero I; Peláez-García A; Hardisson D; de Andrea CE
J Pathol; 2022 Dec; 258(4):426-436. PubMed ID: 36169332
[TBL] [Abstract] [Full Text] [Related]
7. Multiparametric immune profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: an exploratory study of the CLAP trial.
Wang Y; Lai Y; Peng H; Yan S; Liu Z; Tong C; Huang X
Clin Transl Oncol; 2023 Jan; 25(1):256-268. PubMed ID: 36115931
[TBL] [Abstract] [Full Text] [Related]
8. Presence of regulatory T-cells in endometrial cancer predicts poorer overall survival and promotes progression of tumor cells.
Kolben T; Mannewitz M; Perleberg C; Schnell K; Anz D; Hahn L; Meister S; Schmoeckel E; Burges A; Czogalla B; Hester A; Mahner S; Kessler M; Jeschke U; Corradini S; Trillsch F; Beyer S
Cell Oncol (Dordr); 2022 Dec; 45(6):1171-1185. PubMed ID: 36098901
[TBL] [Abstract] [Full Text] [Related]
9. Role of foxp3-positive regulatory T-cells in regressive and progressive cervical dysplasia.
Vattai A; Kremer N; Meister S; Beyer S; Keilmann L; Hester A; Temelkov M; Heidegger H; Schmoeckel E; Kessler M; Mahner S; Jeschke U; Hertlein L; Kolben T
J Cancer Res Clin Oncol; 2022 Feb; 148(2):377-386. PubMed ID: 34739585
[TBL] [Abstract] [Full Text] [Related]
10. Identifying a cervical cancer survival signature based on mRNA expression and genome-wide copy number variations.
Li N; Yu K; Lin Z; Zeng D
Exp Biol Med (Maywood); 2022 Feb; 247(3):207-220. PubMed ID: 34674573
[TBL] [Abstract] [Full Text] [Related]
11. Prediction of treatment response from the microenvironment of tumor immunity in cervical cancer patients treated with chemoradiotherapy.
Someya M; Tsuchiya T; Fukushima Y; Hasegawa T; Hori M; Kitagawa M; Gocho T; Mafune S; Ikeuchi Y; Hirohashi Y; Torigoe T; Iwasaki M; Matsuura M; Saito T; Matsumoto Y; Sakata KI
Med Mol Morphol; 2021 Sep; 54(3):245-252. PubMed ID: 33963949
[TBL] [Abstract] [Full Text] [Related]
12. Autologous cervical tumor lysate pulsed dendritic cell stimulation followed by cisplatin treatment abrogates foxp3+ cells in vitro.
Dhandapani H; Seetharaman A; Jayakumar H; Ganeshrajah S; Singh SS; Thangarajan R; Ramanathan P
J Gynecol Oncol; 2021 Jul; 32(4):e59. PubMed ID: 33908712
[TBL] [Abstract] [Full Text] [Related]
13. Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis.
Litwin TR; Irvin SR; Chornock RL; Sahasrabuddhe VV; Stanley M; Wentzensen N
Br J Cancer; 2021 Feb; 124(4):831-841. PubMed ID: 33257839
[TBL] [Abstract] [Full Text] [Related]
14. Association between cancer immunity and treatment results in uterine cervical cancer patients treated with radiotherapy.
Someya M; Tsuchiya T; Fukushima Y; Hasegawa T; Takada Y; Hori M; Miura K; Kitagawa M; Gocho T; Hirohashi Y; Torigoe T; Iwasaki M; Matsuura M; Saito T; Sakata KI
Jpn J Clin Oncol; 2020 Oct; 50(11):1290-1297. PubMed ID: 33089868
[TBL] [Abstract] [Full Text] [Related]
15. Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy.
Ohno A; Iwata T; Katoh Y; Taniguchi S; Tanaka K; Nishio H; Nakamura M; Morisada T; Chen G; Saito M; Yaguchi T; Kawakami Y; Aoki D
Gynecol Oncol; 2020 Nov; 159(2):329-334. PubMed ID: 32829964
[TBL] [Abstract] [Full Text] [Related]
16. Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment.
Lippens L; Van Bockstal M; De Jaeghere EA; Tummers P; Makar A; De Geyter S; Van de Vijver K; Hendrix A; Vandecasteele K; Denys H
Int J Cancer; 2020 Jul; 147(2):554-564. PubMed ID: 32017078
[TBL] [Abstract] [Full Text] [Related]
17. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial cancer.
Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
Front Immunol; 2019; 10():3023. PubMed ID: 31998307
[TBL] [Abstract] [Full Text] [Related]
18. Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy.
Tsuchiya T; Someya M; Takada Y; Hasegawa T; Kitagawa M; Fukushima Y; Gocho T; Hori M; Nakata K; Hirohashi Y; Torigoe T; Saito T; Sakata KI
Strahlenther Onkol; 2020 Aug; 196(8):725-735. PubMed ID: 31953603
[TBL] [Abstract] [Full Text] [Related]
19. Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer.
Heeren AM; van Luijk IF; Lakeman J; Pocorni N; Kole J; de Menezes RX; Kenter GG; Bosse T; de Kroon CD; Jordanova ES
Cancer Immunol Immunother; 2019 Nov; 68(11):1759-1767. PubMed ID: 31616965
[TBL] [Abstract] [Full Text] [Related]
20. Role of B7-H4 in the Progression and Prognosis of Cervical Inflammation to cancer After Human Papilloma Virus Infection.
Qiu F; Yuan C; Xu J; Zhang J; Chen F; Liu D; Zheng B; Li R; Huang X; Xu J
J Biomed Nanotechnol; 2019 May; 15(5):1043-1051. PubMed ID: 30890234
[TBL] [Abstract] [Full Text] [Related]
[Next]
